Forma Therapeutics, Inc.

Scot Mente

Matthew W Martin

Xiaozhang Zheng

Zhongguo Wang

Christopher J Dinsmore

Mary-Margaret Zablocki

Bingsong Han

Cuixian Liu

Alexandre Joseph Buckmelter

Justin Andrew Caravella

Stephanos Ioannidis

David James Richard

Steven Gregory Mischke

The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

Inhibiting fatty acid synthase (FASN)

The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Protease 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments. Chemical entities disclosed herein include compounds of Formula (II): wherein A, R, R, R, R, R, R, R, R, and m are defined herein.

Inhibiting ubiquitin specific peptidase 30

Growing community of inventors

Watertown, MA, United States of America

Scot Mente